DESIGNED TO BE DIFFERENT
by minimising off-target effects in the treatment of B-cell malignancies2–5
Proven efficacy regardless of line of
therapy, genetic status and patient
populations6-9
A consistent safety profile
demonstrated across B-cell
malignancies for over 5 years9-12
Unmatched BTK inhibitor
dosing flexibility12-14